Superfluid Dx (formerly Molecular Stethoscope) develops a liquid‑biopsy diagnostic that measures cell‑free mRNA released from brain cells and surveys circulating cells to provide a direct and more precise readout of neurodegenerative pathology. The company’s proprietary science and data‑analysis platform is designed to harness cf‑mRNA as a fundamental signal of cellular activity. Preliminary results reported by the company indicate greater accuracy than existing Alzheimer's diagnostic tests that target amyloid, tau and APOE markers. Superfluid’s stated goal is to build the most accurate diagnostic for neurodegenerative diseases. The company is engaging with therapeutics developers to support clinical trials and research. Financially, Superfluid completed an oversubscribed Series A led by WRQ Sciences, which acquired majority ownership. Molecular Stethoscope is a precision-medicine biotechnology company pioneering a next-generation cf-mRNA liquid biopsy AI/ML technology platform. Its proprietary platform integrates whole-transcriptome cf-mRNA with RNA-Seq, clinical data, and purpose-built bioinformatics, machine learning and artificial intelligence to generate clinically actionable, dynamic information. The company is focused on discovering, developing and commercializing non-invasive products for early detection, diagnosis and treatment-response monitoring of chronic diseases, beginning with the liver (NAFLD/NASH) and the central nervous system (Alzheimer's disease and multiple sclerosis). Molecular Stethoscope published an Alzheimer's disease human proof-of-concept study in Science Advances and is moving into the next phase of translational studies to develop clinical-grade products and services. The company aims to enable early, longitudinal and serial diagnosis and monitoring of diseases in both biopsy-accessible and biopsy-inaccessible organs. Molecular Stethoscope was co-founded by Dr. Stephen Quake and Dr. Eric Topol and is based in South San Francisco. Molecular Stethoscope is a San Diego–based biotechnology company developing blood-based early detection and disease monitoring tests using proprietary liquid biopsy technology. The company’s platform leverages circulating cell-free RNA in blood to monitor organ damage and disease in real time; the technology originated in the laboratories of Dr. Stephen Quake and Dr. Eric Topol. Founded in 2015 and led by President and CEO Tina S. Nova, Molecular Stethoscope plans to apply its assays initially in cardiometabolic and neurodegenerative diseases and to accelerate discovery in additional markets. The company completed an $8.2M seed financing and intends to use the proceeds to continue development of its proprietary liquid biopsy tests. It has also signed a two-year research collaboration agreement with Pfizer to develop a blood-based assay to identify subjects at critical stages of disease progression in key cardiometabolic conditions.

Total raised

$8M

Funding rounds

3

Latest round

Seed

Latest activity

Jan 2017